Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood test may reveal kidney damage in lupus — no biopsy needed?

NCT ID NCT07763834

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of lupus nephritis and active lupus without kidney involvement. If uromodulin correlates with biopsy findings, it could become a less invasive way to monitor the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Uromodulin (a protein measured in blood as a potential biomarker)
What this could lead to
If uromodulin levels match biopsy results, it could offer a less invasive way to monitor kidney damage in lupus nephritis, potentially reducing the need for repeated biopsies.
What could go wrong
This is an early, observational study with a small number of participants. Uromodulin may not reliably reflect biopsy findings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Nephrology and Rheumatology unit, Assiut University Hospital

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Group I: 30 patients with different classes of Lupus Nephritis. These cases are biopsy proven LN. Histological diagnosis of LN is according to the revised International Society of Nephrology/ Renal Pathology Society (ISN/RPS) classification and modified National Institute of Health (NIH) activity and chronicity indices (Bajema et al 2018) . * Biopsy-proven lupus nephritis at the time of uromodulin blood sampling. * Group II: 10 patients with active SLE without renal involvement and with SLEDAI score ≥6 * Group III: 10 patients with non-active SLE with SLEDAI score \<6 * Group IV: 30 patients with primary forms of non-lupus Glomerulonephritis * Group V: 10 healthy control subjects * All cases are adults ≥18 years. * Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR Classification Criteria (Ref).Exclusion Criteria: * • .Pregnancy or lactation * AKI secondary to pre renal OR post renal cause (from clinical history and imaging). * End-stage renal disease requiring dialysis * Active infection or sepsis * Active malignancy (either under treatment or within 5 years of successful treatment) * History of renal transplantation * Heart failure with NYHA III and IV * Hhistory of other autoimmune diseases or diabetes mellitus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glomerulonephritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glomerulonephritis lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE Uromodulin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.